Xue X-X, Lei H-Q, Zhao L, Wang X-Y, Wang Z, Xie L-Y, Jia J-H
Department of Nephrology, Weinan Central Hospital, Weinan, Shaanxi Province, China.
Eur Rev Med Pharmacol Sci. 2020 May;24(9):5018-5027. doi: 10.26355/eurrev_202005_21193.
To investigate the effects of the downregulation of AGER by miRNA-185-3p on renal function in diabetic nephropathy (DN) mice.
Mice were divided into normal, model, NC, miR-185-3p mimic, si-AGER, and miR-185-3p mimic + si-AGER groups. Eight weeks following the establishment of the model, various indicators were assessed.
Compared to control groups, miR-185-3p expression, body weight, superoxide dismutase (SOD) content, catalase (CAT) content, proliferation, S-phase ratios, and proliferating cell nuclear antigen (PCNA) expression were significantly lower in all experimental groups, whilst AGER expression, water intake, food intake, urine volume, urine protein content, serum creatinine (Scr), Blood Urea Nitrogen (BUN), MDA content, G0/G1 status, and rates of apoptosis were significantly higher (all p<0.05). Compared to the model group, miR-185-3p mimics, si-AGER, and miR-185-3p mimic + si-AGER groups had a significantly higher SOD content, CAT content, proliferation, S phase ratios, PCNA expression and lower AGER expression, water intake, food intake, urine output, urine protein, Scr, BUN, MDA content, G0/G1 ratios, and apoptosis rates (all p<0.05). In addition, the effects of the miR-185-3p mimics + si-AGER were superior to miR-185-3p mimics and si-AGER monotherapy groups (both p<0.05).
MiR-185-3p inhibits AGER, downregulates AGER expression, and improves renal function in DN mice.
探讨miRNA-185-3p下调晚期糖基化终产物受体（AGER）对糖尿病肾病（DN）小鼠肾功能的影响。
将小鼠分为正常组、模型组、阴性对照组、miR-185-3p模拟物组、si-AGER组和miR-185-3p模拟物+si-AGER组。造模8周后，评估各项指标。
与对照组相比，各实验组miR-185-3p表达、体重、超氧化物歧化酶（SOD）含量、过氧化氢酶（CAT）含量、增殖、S期比例及增殖细胞核抗原（PCNA）表达均显著降低，而AGER表达、饮水量、摄食量、尿量、尿蛋白含量、血清肌酐（Scr）、血尿素氮（BUN）、丙二醛（MDA）含量、G0/G1期状态及凋亡率均显著升高（均p<0.05）。与模型组相比，miR-185-3p模拟物组、si-AGER组和miR-185-3p模拟物+si-AGER组的SOD含量、CAT含量、增殖、S期比例、PCNA表达显著升高，而AGER表达、饮水量、摄食量、尿量、尿蛋白、Scr、BUN、MDA含量、G0/G1比例及凋亡率显著降低（均p<0.05）。此外，miR-185-3p模拟物+si-AGER组的效果优于miR-185-3p模拟物组和si-AGER单药治疗组（均p<0.05）。
MiR-185-3p抑制AGER，下调AGER表达，改善DN小鼠肾功能。
